Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 4:6:65-72.
doi: 10.4137/CMAMD.S10951. eCollection 2013.

Regenerative injection therapy with whole bone marrow aspirate for degenerative joint disease: a case series

Affiliations

Regenerative injection therapy with whole bone marrow aspirate for degenerative joint disease: a case series

Ross A Hauser et al. Clin Med Insights Arthritis Musculoskelet Disord. .

Abstract

Regenerative therapeutic strategies for joint diseases usually employ either enriched concentrates of bone marrow-derived stem cells, chondrogenic preparations such as platelet-rich plasma, or irritant solutions such as hyperosmotic dextrose. In this case series, we describe our experience with a simple, cost-effective regenerative treatment using direct injection of unfractionated whole bone marrow (WBM) into osteoarthritic joints in combination with hyperosmotic dextrose. Seven patients with hip, knee or ankle osteoarthritis (OA) received two to seven treatments over a period of two to twelve months. Patient-reported assessments were collected in interviews and by questionnaire. All patients reported improvements with respect to pain, as well as gains in functionality and quality of life. Three patients, including two whose progress under other therapy had plateaued or reversed, achieved complete or near-complete symptomatic relief, and two additional patients achieved resumption of vigorous exercise. These preliminary findings suggest that OA treatment with WBM injection merits further investigation.

Keywords: bone marrow aspirate; case series; chronic pain; osteoarthritis; prolotherapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kelsey JL, Hochberg MC. Epidemiology of chronic musculoskeletal disorders. Ann Rev Public Health. 1988;9:379–401. - PubMed
    1. Yelin EH, Trupin LS, Sebesta DS. Transitions in employment, morbidity, and disability among persons ages 51–61 with musculoskeletal and non-musculoskeletal conditions in the US, 1992–94. Arthr Rheum. 1999;42(4):769–79. - PubMed
    1. DeChellis DM, Cortazzo MH. Regenerative medicine in the field of pain medicine: Prolotherapy, platelet-rich plasma therapy, and stem cell therapy—Theory and evidence. Phys Med Rehab Pain Specialist. 2012;15(2):74–80.
    1. Nejadnik H, Hui JH, Choong EPF, Tai BC, Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation an observational cohort study. Am J Sports Med. 2010;38(6):1110–6. - PubMed
    1. Ossendorf C, Steinwachs MR, Kreuz PC, et al. Autologous chondrocyte implantation (ACI) for the treatment of large and complex cartilage lesions of the knee. Sports Med Arthrosc Rehabil Ther Technol. 2011;3:11. - PMC - PubMed

LinkOut - more resources